Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in high-risk nasopharyngeal carcinoma
NCT03925090Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nasopharyngeal carcinoma (NPC) comparing Neoadjuvant and Adjuvant Toripalimab+CCRT with Neoadjuvant and Adjuvant Placebo+CCRT (2 arms). Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03925090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03925090.